Table 2.
Multivariate analysis of factors associated with relapse and reinfection among 98 patients with confirmed RFLP results
| Relapse | Reinfection | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Events | Rate per 100 PYO | HR (95%CI) | aHR (95%CI) | Events | Rate per 100 PYO | HR (95%CI) | aHR (95%CI) | |
| Overall | 98 | 80 | 1.0 | 18 | 0.7 | ||||
| HIV status* | |||||||||
| Positive | 57 | 45 | 1.0 | 0.8 (0.5–1.2) | 0.4 (0.2–0.8) | 12 | 0.6 | 0.8 (0.3–2.5) | 0.6 (0.1–3.6) |
| Negative | 40 | 34 | 1.1 | Reference | 6 | 1.0 | Reference | ||
| Hemoglobin, g/dl† | |||||||||
| <12 | 69 | 57 | 1.2 | 1.4 (0.9–2.4) | 2.2 (1.1–4.7) | 12 | 0.7 | 0.8 (0.3–2.3) | 0.8 (0.2–3.8) |
| ⩾12 | 29 | 23 | 0.8 | Reference | 6 | 0.7 | Reference | ||
| Weight gain at 2 months, kg† | |||||||||
| <3 | 62 | 54 | 1.1 | 1.1 (0.7–1.7) | 1.2 (0.6–2.4) | 8 | 0.7 | 1.0 (0.4–3.1) | 1.5 (0.4–6.3) |
| ⩾3 | 36 | 26 | 1.0 | Reference | 10 | 0.8 | Reference | ||
| Continuation phase regimen‡ | |||||||||
| 6H3E3 | 9 | 7 | 1.4 | 1.2 (0.5–2.6) | 1.4 (0.6 3.5) | 2 | 0.6 | 1.0 (0.2–4.6) | 1.6 (0.2–11.2) |
| 6RH | 7 | 7 | 0.7 | 0.7 (0.3–1.5) | 0.8 (0.3–2.3) | 0 | — | — | — |
| 4RH | 82 | 66 | 1.1 | Reference | 16 | 0.7 | Reference | — | |
| Fibrosis (end of treatment)§ | |||||||||
| Yes | 31 | 26 | 1.1 | 1.0 (0.6–1.6) | 0.9 (0.5–1.7) | 5 | 1.3 | 3.0 (0.9–10.0) | 3.9 (1.0–15.8) |
| No | 52 | 41 | 1.0 | Reference | 11 | 0.6 | Reference | ||
*
HIV status missing for 1 patient (relapse).
†
Variable dichotomized based on median value.
‡
Numbers before the letters indicate the duration in months of the phase of treatment; numbers in subscript indicate the number of times the drug is taken each week.
§
Variable missing for 15 patients (13 relapse; 2 reinfection).
RFLP = restriction fragment length polymorphism; PYO = person-years of observation; HR = hazard ratio; CI = confidence interval; aHR = adjusted HR; HIV = human immunodeficiency virus; H = isoniazid; E = ethambutol; R = rifampicin.